New hope for tough breast cancer: drug cocktail trial launches
NCT ID NCT07330544
First seen Jan 11, 2026 · Last updated Jun 16, 2026 · Updated 27 times
Summary
This study tests whether adding two drugs (entinostat and anlotinib) to a standard hormone therapy (fulvestrant) can shrink tumors or slow cancer growth in people with a common type of advanced breast cancer (HR+/HER2-). About 118 adults whose cancer returned or worsened after prior hormone therapy will receive the drug combinations. The goal is to see if the new combinations work better than current options, while monitoring side effects closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGZhejiang, Hangzhou, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.